Otsuka America Pharmaceutical's North American BreathTek business has been bought by Meridian Bioscience in a deal worth $20 million. Meridian Bioscience will assume customer relationships to supply BreathTek, a urea breath test used to detect Helicobacter pylori.
Equip your lab to handle the opioids crisis Synthetic opioids are the main drivers of drug overdoses. Fast, reliable testing can help you triage patients and save lives. Learn more about how Siemens Healthineers can help your laboratory provide important testing solutions during this crisis.
EU antitrust regulators said they have opened an investigation to determine whether the $8 billion cash and stock acquisition of cancer test startup Grail by Illumina will reduce innovation and competition. Meanwhile, the US Federal Trade Commission is attempting to block the deal.
The next health care crisis? While the COVID-19 pandemic ushered in a global care crisis, it was also creating a perfect storm for the next health care crisis - an increase in opioid abuse. Health care professionals across the industry must be prepared for this next health care crisis, and they need to be able to identify and care for the vulnerable patients affected. Join mental health experts and health care professionals in this webinar.
The FDA has given emergency use authorization to Ortho Clinical Diagnostics for its Vitros Immunodiagnostic Products Anti-SARS-CoV-2 Total N Reagent Pack that is used with its Vitros Immunodiagnostic Products Anti-SARS-CoV-2 Total N Antibody Calibrators to detect total antibodies against SARS-CoV-2 in plasma and serum.
Abbott generated $10.2 billion in sales and $1.2 billion in profits during its fiscal second quarter, which ended June 30. "Excluding COVID testing-related sales, our sales grew more than 11 percent on an organic basis compared to pre-pandemic levels in the second quarter of 2019, which demonstrates the fundamental strength of our performance," said Robert Ford, Abbott's CEO and president.
Danaher generated $7.2 billion in sales and $1.7 billion in profits during its fiscal second quarter, which ended July 2. "We continued to make significant growth investments during the quarter, strengthening our organic growth trajectory and enhancing our portfolio with the announcement of our pending acquisition of Aldevron," said Rainer Blair, president and CEO of Danaher.
Join colleagues at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, showcasing the cutting-edge science and technology shaping the future of laboratory medicine. Early Discounts Expire Thursday, July 29!